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PPN5
COMPARISON OF COSTS AND
COST-EFFECTIVENESS OF OXCARBAZEPINE 
AND SODIUM VALPROATE FOR
NEW/RECENT ONSET PARTIAL SEIZURES
Bazalo G1, Sachdeo R2, Graham S3, Chang S3, Cohen A3
1Bazalo Consulting, Scottsdale, AZ, USA; 2Robert Wood 
Johnson Medical School, New Brunswick, NJ, USA; 3Novartis 
Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVE: to determine the comparative costs and
cost-effectiveness of oxcarbazepine and sodium valproate
in the treatment of new and recent onset partial epileptic
seizures. METHODS: Low, moderate and high dose
maintenance regimens were determined for each drug
based upon prescription audit information captured in
the prescribing physician’s office. Unit drug costs based
on wholesale acquisition costs were then used to compute
a daily drug cost for each dosage level. A decision-analy-
sis model using a Monte Carlo simulation was developed
to evaluate the cost-effectiveness of oxcarbazepine and
sodium valproate. The model contained the computed
daily drug costs along with direct payer costs associated
with initiation and maintenance of therapy, treatment of
adverse events and switching from one drug to another
due to poor seizure control or adverse events. The proba-
bilities of maintaining seizure control and of experiencing
adverse events were obtained from double-blind clinical
trials comparing oxcarbazepine and sodium valproate.
RESULTS: The average daily drug costs weighted over
the three dosage levels were $4.72 ($1.49 to $7.66) for
oxcarbazepine and $3.17 ($2.45 to $3.87) for sodium
valproate. Total one year costs for oxcarbazepine, includ-
ing costs of adverse events and costs of switching drugs
due to poor seizure control or adverse events were
$3,511 for oxcarbazepine and $5,931 for sodium val-
proate. The computed number of months on initial ther-
apy was 9.95 for oxcarbazepine and 9.66 for sodium val-
proate. The analysis was carried out to four years using
the same probabilities for adverse events and seizure con-
trol. The four-year costs were $17,949 and $23,144 with
25.8 and 24.3 months of therapy for oxcarbazepine and
sodium valproate respectively. CONCLUSION: These
findings suggest that oxcarbazepine results in lower ex-
pected total costs compared to sodium valproate when
drug costs, evaluation and management, adverse events
and costs of switching therapies are taken into account.
PPN6
VALIDATION OF THE 24 HOUR HEADACHE 
DISABILITY QUESTIONNAIRE (DISQ-24) IN A 
SAMPLE OF HEADACHE SUFFERERS
Runken MC, Kwong W, Davis K, Batenhorst A
GlaxoSmithKline, Inc, Research Triangle Park, NC, USA
OBJECTIVES: The Disq-24 was developed to measure
headache disability on a 24-hour basis and was first uti-
lized in a sample of migraine subjects who experienced
chronic daily headaches. The purpose of this study was to
evaluate this instrument’s psychometric properties.
METHODS: The Disq-24 is a 14-item questionnaire with
a 6-point Likert-type scale that measures disability with
regards to three hypothesized dimensions: family/social
(4-item), work activities (5-item), and emotions/feelings
(5-item). This instrument was administered in a prospec-
tive, multicenter, randomized, double-blind, placebo-
controlled, parallel group trial of 170 transformed mi-
graine sufferers. Four scaling assumptions of summated
rating scales (equal variances, equal weights, item-inter-
nal consistency and discriminant validity) and scale-level
reliability were examined using the baseline data. RE-
SULTS: The means and standard deviations of items
within each scale were similar. However, item evaluation
demonstrated a floor effect in all items ranging from
22% to 66%. Item internal consistency was generally
high and ranged from 0.62 to 0.90. Cronbach’s alpha
ranged from 0.93 to 0.95 for the three dimensions and
was 0.97 for the total score, exceeding the generally ac-
ceptable criteria of 0.70. Although each item was highly
correlated with the hypothesized scale, the item-scale cor-
relations did not discriminate significantly with other
scales. CONCLUSIONS: Although the Disq-24 satisfied
the equal variance, equal weights, and internal consis-
tency assumptions of summated rating scales, item dis-
criminant validity was not supported in the above analy-
sis. This lack of support could be due to the small sample
size and/or the existence of a unidimensional structure.
The validity of the instrument warrants further testing in
a headache population which is not restricted to chronic
daily headache patients.
PPN7
A MODEL FOR PREDICTING THE INCIDENCE
OF MIGRAINE IN THE IDAHO
MEDICAID POPULATION
Shaw J1, Joish V1, Cady PS2
1The University of Arizona, Tucson, AZ, USA; 2Idaho State 
University, Pocatello, ID, USA
BACKGROUND: Migraine headache affects approxi-
mately 9 million Americans. It is a chronic disease and is
often associated with a high rate of disability. OBJEC-
TIVE: The purpose of this research was to develop a
model for predicting the incident number of migraine
cases in the Idaho Medicaid population over a 5-year pe-
riod. METHODS: Incident migraine cases between Janu-
ary 1994 and December 1998 were identified from the
Idaho Medicaid claims database using migraine-specific
ICD-9-CM codes or migraine-specific pharmacy claims.
Data were collected on the total number of new migraine
cases according to age, race, gender, and year. A negative
binomial model was developed to predict incident mi-
graine cases from the other variables. All model indepen-
dents were treated as categorical variables. Two hundred
sixty-six Medicaid recipients between the ages of 5 and
104 were included in the analysis. RESULTS: A test for
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overdispersion revealed that use of a negative binomial
model was appropriate. Age, race, gender, and year were
all determined to be significant effects by likelihood-ratio
test. The greatest incidence of migraine was observed
among persons 30–34 years of age. Controlling for other
effects, the incidence of migraine fell with increasing age
34 or decreasing age 30. The estimated mean number
of new cases was greater among Caucasians than non-
Caucasians (46.2 vs. 3.7) and was greater among females
than males (41.9 vs. 8.0). The estimated incidence of mi-
graine was lowest in 1994 and generally rose each year
from 1996 onward. Using a pseudo-R2 measure devel-
oped by Nagelkerke, the model explained 87.2% of the
variance in incident migraine cases. CONCLUSIONS:
The findings of this investigation with regard to age, race,
and gender are consistent with those of previous studies.
Our estimates for the impact of time on the incidence of
migraine suggest that costs associated with migraine
treatment will continue to rise for the Idaho Medicaid
program.
PPN8
PSYCHOMETRIC EVALUATION OF WIDELY 
USED PAIN MEASURES FOR PURPOSE OF 
COMPUTERIZED DYNAMIC PAIN ASSESSMENT
Zhao JH1, Ware JE1, Kosinski M1, Bjorner JB2,
Turner-Bowker D1
1QualityMetric, Lincoln, RI, USA; 2National Institute of 
Occupational Health, Copenhagen, Denmark
OBJECTIVES: The aim of this study was to test the uni-
dimensionality of 65 items from nine widely used pain
questionnaires in preparation for computerized adaptive
pain assessment. METHODS: Random samples of adults
were contacted on the internet (N  782) and telephone
(N  750). 65 items were selected mainly from Brief Pain
Inventory, MOS Pain Measures, Oswestry Low Back
Pain Disability Questionnaire, NottingHam Health Pro-
file, McGill Pain Questionnaire, Health Disability Index,
Migraine-Specific Questionnaire, Aberdeen Back Pain
Scale, and Headache Impact Test. Mplus software was
used to perform confirmatory and exploratory factor
analyses of polychoric correlations among the items.
Model was examined through eigenvalue analysis, inter-
factor correlations, and root mean square residuals. RE-
SULTS: Confirmatory factor loadings ranged from 0.53
to 0.92 with 90% of them higher than 0.7. Three factors
were rotated to an oblique solution. Examination of ex-
ploratory factor analysis revealed two subdimensions of
pain based upon item content: pain severity and pain im-
pact. The third dimension observed in the three-factor so-
lution, interpreted as current pain, was defined by ques-
tions without recall period. Eigenvalue analyses showed
that the first factor explained more than 65 percent of the
total variance in all pain item scores. Three factors ex-
plained 74% of the variance. The interfactor correlations
were high, ranged from 0.64 to 0.67. Root mean square
residuals were low, 0.07 for one-factor solution and
0.05, 0.03 for two- and three-factor solution respectively.
CONCLUSION: Most items from widely used question-
naires measure one single underlying construct of pain
sufficiently to meet the assumption of Item Response
Theory. Items selected will be calibrated on a standard
metric to estimate scores at patient’s specific pain level.
Further investigation on the application of IRT methods
and computer technology in pain assessment is war-
ranted.
PPN9
HOW IS PAIN FELT ACROSS COUNTRIES? THE 
SHORT-FORM MCGILL PAIN QUESTIONNAIRE 
(SF-MPQ) IN 10 LANGUAGES
Conway K1, Uzun V1, Alacoque J1, Abetz L2, Melzack R3, 
Plante M4
1Mapi Research Institute, Lyon, France; 2Mapi Values, 
Macclessfield, UK; 3McGill University, Montreal, QC, Canada; 
4Pfizer Inc, Ann Arbor, MI, USA
OBJECTIVES: Measuring Health-Related Quality of Life
(HRQoL) has become a vital part of assessing pain in in-
ternational studies. The SF-MPQ is one of the most
widely used tests for the measurement of pain. It consists
of 15 descriptors (11 sensory; 4 affective) rated on an in-
tensity scale from 0 (none) to 3 (severe), a Present Pain
Intensity (PPI) Index and a visual analogue scale (VAS).
Prior to use in international trials the measure underwent
linguistic validation in 10 languages. METHODS: A
HRQoL specialist coordinated the translation process in
each target country using the following methodology: 1)
two forward translations by professional translators, na-
tive speakers of the target language and fluent in English;
2) comparison and reconciliation of the translations by a
HRQoL specialist and translators; 3) backward transla-
tion by a native English speaker; 4) comparison of the
source and backward versions; 5) comprehension test in
a sample target population and finalization. RESULTS:
Linguistic and conceptual issues emerged during the trans-
lation process. The adjective “aching” was redundant in
most languages, equivalents were found such as “discom-
forting”/“not very intense”. The adjective “tender” used
alone was not found descriptive; the equivalent “sensitive
to touch” was therefore preferred. The term “punishing”
was found to have a strong religious connotation, the no-
tions of “violent” or “torturing” were used instead. Con-
cerning the PPI Index, the terms used to describe pain
had an affective component such as “distressing”, “horri-
ble”. An intensity scale was favored in translations.
CONCLUSIONS: A rigorous translation methodology of
the original SF-MPQ was performed to ensure conceptual
equivalence and acceptability of translations. The issues
encountered during linguistic validation highlight the
value of international input in instrument design. Future
psychometric testing will be conducted to ensure reliabil-
ity and validity of each translation, appropriateness of
the questionnaire in each country, and comparability of
data across countries.
